Bio Studio program collaboration to create life science start-ups

The BioInnovation Institute (BII) has partnered with Imperial College London in the UK to launch a new translation project as part of its Bio Studio programme.

The program aims to encourage the creation of new life science start-ups based on research for the benefit of people and society.

Based in Denmark, BII is an international commercial, non-profit foundation that promotes and advances life science research.

As part of the collaboration, Molly Stevens, Professor of Biomedical Materials and Regenerative Medicine at Imperial College London, will lead a translational healthtech research project.

The aim of the project is to provide a transformative approach to the early detection and monitoring of debilitating diseases through the development of an ultra-sensitive target-agnostic biosensor platform. Research will focus on diseases that could potentially address major global public health challenges. The technology is intended to be deployed as a low-cost diagnostic platform, enabling artificial intelligence-based evaluation of molecular fingerprints to inform clinical decisions with the aim of slowing disease progression and improving treatment plans.


BII will support the project with an in-kind grant of up to 6.5 million DKK ($870,000) per year for a project period of up to three years, as well as business development expertise, intellectual property support, investor network and infrastructure.

Other Projects

BII recently launched the Bio Studio program with the aim of building and operating a leading life science company creation facility in Europe. The present project follows a collaboration with the European Molecular Biology Laboratory (EMBL) in Heidelberg, announced in June this year.

Also Read :  Bright Idea: Science Friday’s Sun Camp!

Markus Herrgård, Chief Technology Officer at BII, said: “We are very pleased to be working with Prof. Stevens and her team on the Bio Studio program. The program focuses on accelerating the development and commercialization of cutting-edge technology through partnerships with leading research institutions and entrepreneurial academics. As a globally recognized leader in diagnostic biosensing with a strong entrepreneurial background, Prof. Stevens is an excellent fit for the program.”

Stevens said: “Translating research results to reach those most in need has been a central focus of my research career. I’m a passionate advocate for the democratization of medicine and the accessibility of healthcare for all. Working with the BII in the Bio Studio program will enable my team to achieve these goals for the benefit of patients. I very much look forward to working with a team of professionals, including a dedicated entrepreneur-in-residence, to translate our science into innovative products and solutions.”

Also Read :  Families get hands-on learning at Cool Science Carnival Day at UCCS | Education

Since its inception in 2018, BII has backed 62 startups and projects with €50 million ($49.6 million), along with venture capital, industry and business expertise it provides to help them take them to the next level to reach. In total, BII’s startups have raised more than €207 million (US$205 million) in external funding from local and international investors. Recent company successes include Adcendo, Stipe Therapeutics, Twelve Bio, Octarine Bio and Cirqle Biomedical.

Source link